FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2282094328> ?p ?o ?g. }

• W2282094328 endingPage "43" @default.
• W2282094328 startingPage "43" @default.
• W2282094328 abstract "Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center Michele Carron, Fabio Baratto, Francesco Zarantonello, Carlo Ori Department of Medicine, Anesthesiology and Intensive Care, University of Padova, Padova, Italy Objective: The aim of the study is to evaluate the clinical and economic impact of introducing a rocuronium–neostigmine–sugammadex strategy into a cisatracurium–neostigmine regimen for neuromuscular block (NMB) management. Methods: We conducted a retrospective analysis of clinical outcomes and cost-effectiveness in five operating rooms at University Hospital of Padova. A clinical outcome evaluation after sugammadex administration as first-choice reversal drug in selected patients (rocuronium–sugammadex) and as rescue therapy after neostigmine reversal (rocuronium–neostigmine–sugammadex) compared to control was performed. A cost-analysis of NMB management accompanying the introduction of a rocuronium–neostigmine–sugammadex strategy into a cisatracurium–neostigmine regimen was carried out. To such purpose, two periods were compared: 2011–2012, without sugammadex available; 2013–2014, with sugammadex available. A subsequent analysis was performed to evaluate if sugammadex replacing neostigmine as first choice reversal drug is cost-effective. Results: The introduction of a rocuronium–neostigmine–sugammadex strategy into a cisatracurium–neostigmine regimen reduced the average cost of NMB management by 36%, from €20.8/case to €13.3/case. Patients receiving sugammadex as a first-choice reversal drug (3%) exhibited significantly better train-of-four ratios at extubation (P<0.001) and were discharged to the surgical ward (P<0.001) more rapidly than controls. The cost-saving of sugammadex as first-choice reversal drug has been estimated to be €2.9/case. Patients receiving sugammadex as rescue therapy after neostigmine reversal (3.2%) showed no difference in time to discharge to the surgical ward (P=0.44) compared to controls. No unplanned intensive care unit (ICU) admissions with rocuronium–neostigmine–sugammadex strategy were observed. The potential economic benefit in avoiding postoperative residual curarization (PORC)-related ICU admission in the 2013–2014 period was estimated at an average value of €13,548 (€9,316–€23,845). Conclusion: Sugammadex eliminated PORC and associated morbidities. In our center, sugammadex reduced the costs of NMB management and promoted rapid turnover of patients in operating rooms, with total cost-effectiveness that counteracts the disadvantages of its high cost. Keywords: neuromuscular blockade; neuromuscular blocking agents; rocuronium; sugammadex; postoperative residual curarization; cost-benefit analysis." @default.
• W2282094328 created "2016-06-24" @default.
• W2282094328 creator A5006338020 @default.
• W2282094328 creator A5052556867 @default.
• W2282094328 creator A5055619840 @default.
• W2282094328 creator A5081063035 @default.
• W2282094328 date "2016-02-01" @default.
• W2282094328 modified "2023-10-03" @default.
• W2282094328 title "Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center" @default.
• W2282094328 cites W146197328 @default.
• W2282094328 cites W1526265518 @default.
• W2282094328 cites W1964810444 @default.
• W2282094328 cites W1971623690 @default.
• W2282094328 cites W1972683943 @default.
• W2282094328 cites W1979448748 @default.
• W2282094328 cites W1986729191 @default.
• W2282094328 cites W1987602524 @default.
• W2282094328 cites W1991888689 @default.
• W2282094328 cites W1994789410 @default.
• W2282094328 cites W1999831583 @default.
• W2282094328 cites W2001842562 @default.
• W2282094328 cites W2015847732 @default.
• W2282094328 cites W2018039838 @default.
• W2282094328 cites W2024809703 @default.
• W2282094328 cites W2035530535 @default.
• W2282094328 cites W2044173572 @default.
• W2282094328 cites W2059320961 @default.
• W2282094328 cites W2063672892 @default.
• W2282094328 cites W2065678670 @default.
• W2282094328 cites W2069798907 @default.
• W2282094328 cites W2072883598 @default.
• W2282094328 cites W2075222792 @default.
• W2282094328 cites W2075247534 @default.
• W2282094328 cites W2080204292 @default.
• W2282094328 cites W2081947716 @default.
• W2282094328 cites W2082753953 @default.
• W2282094328 cites W2083841082 @default.
• W2282094328 cites W2097156834 @default.
• W2282094328 cites W2097971041 @default.
• W2282094328 cites W2098647644 @default.
• W2282094328 cites W2101006797 @default.
• W2282094328 cites W2102669415 @default.
• W2282094328 cites W2112757140 @default.
• W2282094328 cites W2113994462 @default.
• W2282094328 cites W2117195234 @default.
• W2282094328 cites W2132695086 @default.
• W2282094328 cites W2139013122 @default.
• W2282094328 cites W2147848022 @default.
• W2282094328 cites W2149733694 @default.
• W2282094328 cites W2151262930 @default.
• W2282094328 cites W2156643345 @default.
• W2282094328 cites W2157806076 @default.
• W2282094328 cites W2166843346 @default.
• W2282094328 cites W2168157935 @default.
• W2282094328 cites W2401096883 @default.
• W2282094328 cites W2402462613 @default.
• W2282094328 cites W2417718136 @default.
• W2282094328 doi "https://doi.org/10.2147/ceor.s100921" @default.
• W2282094328 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4762464" @default.
• W2282094328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26937203" @default.
• W2282094328 hasPublicationYear "2016" @default.
• W2282094328 type Work @default.
• W2282094328 sameAs 2282094328 @default.
• W2282094328 citedByCount "41" @default.
• W2282094328 countsByYear W22820943282016 @default.
• W2282094328 countsByYear W22820943282017 @default.
• W2282094328 countsByYear W22820943282018 @default.
• W2282094328 countsByYear W22820943282019 @default.
• W2282094328 countsByYear W22820943282020 @default.
• W2282094328 countsByYear W22820943282021 @default.
• W2282094328 countsByYear W22820943282022 @default.
• W2282094328 countsByYear W22820943282023 @default.
• W2282094328 crossrefType "journal-article" @default.
• W2282094328 hasAuthorship W2282094328A5006338020 @default.
• W2282094328 hasAuthorship W2282094328A5052556867 @default.
• W2282094328 hasAuthorship W2282094328A5055619840 @default.
• W2282094328 hasAuthorship W2282094328A5081063035 @default.
• W2282094328 hasBestOaLocation W22820943281 @default.
• W2282094328 hasConcept C141071460 @default.
• W2282094328 hasConcept C2776277131 @default.
• W2282094328 hasConcept C2776988050 @default.
• W2282094328 hasConcept C2777411258 @default.
• W2282094328 hasConcept C2778560516 @default.
• W2282094328 hasConcept C2781413609 @default.
• W2282094328 hasConcept C2909465803 @default.
• W2282094328 hasConcept C42219234 @default.
• W2282094328 hasConcept C71924100 @default.
• W2282094328 hasConceptScore W2282094328C141071460 @default.
• W2282094328 hasConceptScore W2282094328C2776277131 @default.
• W2282094328 hasConceptScore W2282094328C2776988050 @default.
• W2282094328 hasConceptScore W2282094328C2777411258 @default.
• W2282094328 hasConceptScore W2282094328C2778560516 @default.
• W2282094328 hasConceptScore W2282094328C2781413609 @default.
• W2282094328 hasConceptScore W2282094328C2909465803 @default.
• W2282094328 hasConceptScore W2282094328C42219234 @default.
• W2282094328 hasConceptScore W2282094328C71924100 @default.
• W2282094328 hasLocation W22820943281 @default.
• W2282094328 hasLocation W22820943282 @default.

• next